Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 12 sources · 7 days · First seen 17 days ago · Last updated 10 days ago

Advancements in melanoma immunotherapy research

Overview

BriaCell Therapeutics has reported a genetic engineering milestone for Bria-MEL+, its personalized whole-cell melanoma immunotherapy vaccine candidate. The company intends to utilize a saliva test to match patients with premanufactured treatment cell lines, a method designed to provide a personalized approach while maintaining the accessibility of an ‘off-the-shelf’ vaccine by eliminating individualized manufacturing.

This development occurs amid broader research activity in the immunotherapy sector, including collaborations such as the partnership between Evotec SE and Plectonic Biotech to target solid tumors using logic-gated DNA-protein technology and costimulatory antibody platforms.

Entities

BriaCell Therapeutics · American Cancer Society · Evotec SE · Miguel A. Lopez-Lago · William V. Williams

Timeline

10 days ago

[HEALTH] 3 sources
Immunotherapy advancements reported by Evotec, Plectonic, and BriaCell
Evotec and Plectonic Biotech are collaborating on a new T-cell immunotherapy for solid tumors, while BriaCell Therapeutics advances its personalized whole-cell melanoma vaccine candidate.
17 days ago

[HEALTH] 9 sources
BriaCell advances personalized melanoma vaccine candidate
BriaCell Therapeutics has reached a genetic engineering milestone for Bria-MEL+, a personalized yet off-the-shelf melanoma immunotherapy vaccine candidate moving toward clinical development.

Sources

atarde.com.br · corrierenazionale.it · drweb.de · em.com.br · epochtimes.de · evotec.com · insideprecisionmedicine.com · investingnews.com · pmlive.com · radiosuper.com.br · srnnews.com · weekendpost.co.bw